

DOCKET NO.: ISPH-0595 (ISIS.019A)  
Appl. No. 09/923,515

PATENT

## **SUMMARY OF THE INTERVIEW**

### **Identification of Claims Discussed**

All of the pending claims were discussed.

### **Principal Arguments and Other Matters**

Applicants' representatives discussed references found in the Examiner's search.

Applicants' representatives proposed amendments to place the claims in condition for allowance.

### **Results of Interview**

No agreement was reached with the Examiner regarding the proposed amendments. The Examiner agreed to consider the proposed amendments in a supplemental reply.

DOCKET NO.: ISPH-0595 (ISIS.019A)  
Appl. No. 09/923,515

PATENT

### REMARKS

Applicants wish to thank Examiner Gibbs for the courteous personal interview conducted on June 28, 2006 to discuss potential claim amendments.

Following entry of the amendments provided herewith, Claims 1, 5, 7, 9, 10, 12, 15, and 41-58 will be pending. Claims 2-4, 6, 8, 11, 13, 14, and 16-40 are canceled. Claims 1, 15, and 41 are currently amended. Claims 51-58 are newly introduced. No new matter is introduced by way of these amendments.

Claim 1 is amended to insert proposed language discussed during the interview conducted on June 28, 2006. Claim 1 as amended herewith recites oligonucleotides targeted to nucleotides 174 to 203 of SEQ ID NO: 3, and additionally recites that the oligonucleotides have 100% complementarity to SEQ ID NO: 3. To the best of Applicants' knowledge, the Examiner's searches have not yielded oligonucleotides having 100% complementarity to SEQ ID NO: 3. Claim 15 is amended to correct antecedent basis.

Claims 51-58 are newly introduced and find support in the specification and claims as originally filed. For example, Claim 51 finds support in Table 1; Claims 52, 53, 57, and 58 find support on page 70, lines 3 through 13 and in Example 15; Claim 54 finds support in the claims as originally filed; and Claim 55 finds support in Table 1.

### Related Co-pending Patent Applications

Applicants make of record the following related, co-pending U.S. Patent Applications:  
U.S. Application Serial No. 10/684,440, filed October 15, 2003  
U.S. Application Serial No. 10/485,113, filed December 2, 2004  
U.S. Application Serial No. 10/559,647, filed December 2, 2005

DOCKET NO.: ISPH-0595 (ISIS.019A)  
Appl. No. 09/923,515


PATENT

### CONCLUSION

Applicants respectfully requests that the claim amendments submitted herewith be entered. In view of the foregoing amendments and remarks, Applicants submit that the application is now in condition for allowance and respectfully requests notification of the same.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 50-0252.

Respectfully submitted,

By:   
Frances R. Putkey, Ph.D.  
Registration No. 57,257

Date: June 30, 2006

ISIS Pharmaceuticals, Inc.  
1896 Rutherford Rd.  
Carlsbad, CA 92008  
Telephone: (760) 603-2710  
Facsimile: (760) 603-3820